Shareholders React Positively as Accelrys Wraps Up SciTegic Deal, Commits to Linux, More M&A | GenomeWeb

Accelrys saw its stock rise 14 percent last Wednesday, following announcements that it had closed its acquisition of SciTegic and committed to release two more software products on the Linux operating system in a partnership with IBM.

The company’s share price, which has steadily declined following its spin-off from Pharmacopeia in early May (see chart, p. 9), jumped by more than 14 percent — to $6.59 from $5.76 — the day following the announcements on Sept. 28.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.